To fund its initiatives to convey MDMA therapy to industry, MAPS Public Benefit Corporation (PBC) — MAPS’ pharma subsidiary, which bifurcated in 2014 but didn't acknowledge investment in return for equity and will not secure the $70 million needed to transfer ahead — has morphed in to the for-gain Lykos Therapeutics.MDMA in the… Read More